Construction and Validation of a Multi-omics Prediction Model to Assess Immunotherapy Efficacy in Patients With Triple-Negative Breast Cancer Subtypes Based on Genomic, Transcriptomic, Proteomic, and Immune Profiling Data
Construction and Validation of a Multi-omics Prediction Model to Assess Immunotherapy Efficacy in Patients With Triple-Negative Breast Cancer Subtypes Based on Genomic, Transcriptomic, Proteomic, and Immune Profiling Data
This study aims to collect clinical samples from breast cancer patients who have undergone or are expected to undergo immunotherapy at our institution. The samples, including fresh tissue from diagnostic punctures, residual tumor tissue post-surgery, blood samples, and imaging data, will be used to build a predictive model for immunotherapy efficacy. The research will employ proteomics, transcriptomics, metabolomics sequencing, imaging mass cytometry (IMC), and spatial transcriptomics to construct a multi-omics, multi-dimensional (temporal and spatial) model to predict the effectiveness of immunotherapy.
This research will utilize a comprehensive approach by analyzing various types of clinical samples from breast cancer patients treated with immunotherapy. The integration of proteomic, transcriptomic, and metabolomic data, along with advanced imaging techniques like IMC and spatial transcriptomics, will allow for a detailed understanding of the tumor microenvironment and its response to immunotherapy. This multi-dimensional analysis aims to enhance the accuracy of predicting immunotherapy outcomes, thereby aiding in personalized treatment strategies for breast cancer patients. The study adheres strictly to ethical guidelines, ensuring patient confidentiality and welfare are maintained throughout the research process.
Inclusion Criteria:
- Female, aged ≥ 18 years.
Pathologically confirmed diagnosis of breast cancer.
Patients who received immunotherapy/neoadjuvant immunotherapy at our institution between January 1, 2015, and September 30, 2023 (retrospective cohort), or patients who may receive immunotherapy/neoadjuvant immunotherapy starting from October 1, 2023 (prospective cohort).
Availability of sufficient tumor tissue samples (e.g., fresh biopsy tissue, residual tumor tissue post-surgery).
Availability of blood samples and imaging data.
Signed informed consent (for the prospective cohort).
Exclusion Criteria:
Inability to provide sufficient tumor tissue samples or other clinical data.
Presence of severe comorbidities (e.g., active infections, severe cardiac, hepatic, or renal dysfunction) that may affect the safety assessment of immunotherapy.
Lack of signed informed consent (for the prospective cohort).